Please use this identifier to cite or link to this item: http://10.1.7.192:80/jspui/handle/123456789/5321
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRaghunathan, Suchi-
dc.date.accessioned2015-01-21T09:19:31Z-
dc.date.available2015-01-21T09:19:31Z-
dc.date.issued2014-
dc.identifier.urihttp://hdl.handle.net/123456789/5321-
dc.descriptionEuropean Journal of Pharmacology 728 (2014) 128–134en_US
dc.description.abstractWehaveevaluatedtheeffectofmagnesiumvalproate(210mg/kg/day,p.o.)intype2diabetesinduced cardiovascularcomplicationsinducedbystreptozotocin(STZ,90mg/kg,i.p.)inneonatalwistarrats.Various biochemical,cardiovascularandhemodynamicparametersweremeasuredattheendof8weeksof treatment.STZproducedsignificanthyperglycaemia,hypoinsulinemiaanddyslipidemia,whichwas preventedbymagnesiumvalproatetreatment.STZproducedincreaseinCreatinineKinase,C-reactive proteinandlactatedehydrogenaselevelsandtreatmentwithmagnesiumvalproateproducedreductionin these levels.STZproducedincreaseincardiacandLVhypertrophyindex,LV/RVratio,LVcollagendeposition andLVcardiomyocytediameterwhichweredecreasedbymagnesiumvalproatetreatment.Magnesium valproatealsopreventedSTZinducedhemodynamicalterationsandoxidativestress.Theseresultswere further supportedbyhistopathologicalstudiesinwhichmagnesiumvalproateshowedmarkedreductionin fibrosisandcardiac fiber disarray.Inconclusion,ourdatasuggeststhatmagnesiumvalproateisbeneficial as ananti-diabeticagentintype-2diabetesmellitusandalsopreventsitscardiaccomplications.en_US
dc.publisherElsevieren_US
dc.relation.ispartofseriesIPFP0129;-
dc.subjectIPFP0129en_US
dc.subjecthyperglycaemiaen_US
dc.titleCardioprotective effects of magnesium valproate in type 2 diabetes mellituen_US
dc.typeFaculty Papersen_US
Appears in Collections:Faculty Papers

Files in This Item:
File Description SizeFormat 
IPFP0129.pdfIPFP01294.45 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.